In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein. ##STR00001##

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Provided herein are Heteroaryl Compounds having the following structure:

##STR00001##

wherein R.sup.1-R.sup.4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.

The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, containing a complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof as an active ingredient. It has been confirmed that a significantly higher synergistic anticancer activity is exhibited in a case where the complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof is administered compared to a case where the biguanide-based compound or a pharmaceutically acceptable salt thereof; and the flavone, hydroxyflavone, flavanone, flavone derivative, hydroxyflavone derivative, flavanone derivative or a pharmaceutically acceptable salt thereof are each administered singly. Consequently, the pharmaceutical composition containing a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof in a complex, mixed or combined manner according to the present invention can be usefully utilized for the prevention or treatment of cancer.

The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, containing a complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof as an active ingredient. It has been confirmed that a significantly higher synergistic anticancer activity is exhibited in a case where the complex, mixed or combined preparation of a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof is administered compared to a case where the biguanide-based compound or a pharmaceutically acceptable salt thereof; and the flavone, hydroxyflavone, flavanone, flavone derivative, hydroxyflavone derivative, flavanone derivative or a pharmaceutically acceptable salt thereof are each administered singly. Consequently, the pharmaceutical composition containing a biguanide-based compound or a pharmaceutically acceptable salt thereof; and a flavone, a hydroxyflavone, a flavanone, a flavone derivative, a hydroxyflavone derivative, a flavanone derivative or a pharmaceutically acceptable salt thereof in a complex, mixed or combined manner according to the present invention can be usefully utilized for the prevention or treatment of cancer.

It provides antibodies and chimeric antigen receptors (CARs) that specifically bind to an epitope containing N-acetyl-glucosamine and/or N-acetyl-galactosamine, e.g., expressed by a cancer cell or an inflammatory cell. Also provided are compositions including these antibodies and/or CARs, as well as polynucleotides, vectors, host cells, methods, and kits related thereto. Further provided are methods and kits for treating or preventing cancer in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, or a T cell comprising a CAR that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, optionally in combination with another anticancer agent.